the invention represents a technological advance in this field , since it improves the release time of ibuprofen , with the beneficial effects that this entails . more specifically , the tablet proposed by the invention focuses its characteristics on the fact that it incorporates two components , which participate therein with the following proportions : as a disaggregating agent , one or a mixture of the following products may be used : the procedure for obtaining and manufacturing the aforementioned tablet involves subjecting the mixture of the two aforementioned products to a dry compaction phase , preferably by means of a refrigerated roller compactor , in order to subsequently transform said compacted product into a granulated product , with the aid of a rotary or rolling granulator . this granulated product may be directly compressed , without adding any other excipient , or it may be mixed with aerosil 200 in a 99 : 1 proportion in order to be compressed . the tablets thus obtained may be 200 -, 400 -, 600 - or 800 - milligram tablets , but the granulate obtained prior to the product compression phase may be directly packed in single - dose sachets . the tablets obtained by means of the procedure of the invention , with any of the aforementioned dosages , may be coated with a protective film of an appropriate nature . the tablets thus obtained have a rate of dissolution of less than 15 minutes for 85 %, according to usp specification xx1v . starting , as previously stated , from ibuprofen in a percentage ranging between 96 % and 97 %, and a disaggregating agent in a proportion ranging between 4 % and 3 %, using any of the aforementioned disaggregating agents , i . e . croscarmellose , crospovidone or sodium carboxymethyl starch , following the mixing of said components , the mixture is compacted in a refrigerated roller compactor at a pressure ranging between 70 and 130 kn , to obtain a compacted wafer that is broken down with a rotary or rolling granulator equipped with a 1 . 5 - to - 2 - mm sieve . the refrigerated rollers must not exceed 25 ° c ., such that the ibuprofen - disaggregating agent mixture does not heat or melt during the compaction action . the refrigeration of the rollers is a critical point in the production process . the refrigeration may be performed with tower water at 10 ° c .- 25 ° c . or with “ cheeler ” water at 7 ° c .- 10 ° c . in summer , refrigeration with tower water presents temperature problems , exceeding the aforementioned limit of 25 ° c . ; for this reason , the rollers are not appropriately refrigerated and this causes alterations in the nature of the granulate . refrigeration with “ cheeler ” water may produce condensations of water in the rollers when the machine is off . in order to avoid this problem , the start - up of the machine entails the automatic opening of the refrigeration of the rollers and vice - versa . this is due to the fact that the activity of the mixing water increases as the temperature decreases , and the greater the aw , i . e . the water activity , the greater the hardness of the compact due to the formation of hydrogen bridges with the residual water in the powder . the residual water in the powder is primarily contributed by the disaggregating agent , and is capable of forming hydrogen bridges with the acid groups of ibuprofen , being greater the greater the water activity ( aw ). on the other hand , 90 % of the granulometry of the starting ibuprofen must be less than 70 μm in diameter . the selection of this ibuprofen with such small particle sizes in order to manufacture tablets is due to the fact that it is desirable to obtain a rapid rate of dissolution under the analytical assay conditions specified by the usp , since for smaller particle sizes the rate of dissolution of the tablet must be greater . but this is only the case when the granulate in contact with the water is dispersed in particle sizes approximately equal to the original ones prior to the compaction . in order for this to be fulfilled , it is necessary that the mixture does not melt during the compaction process . in order to verify this hypothesis , the following assay has been designed : 10 g of granulate are added in a 1 % sodium lauryl sulfate solution ( 100 ml ) and it is stirred for 5 min . after this time , the suspension is run through a sieve of between 70 and 100 μm . the sieve is dried and the percentage of granulate that has been retained in the sieve is determined . at least 90 % of the powder must run through said sieve . once the test has been performed with 3 different batches , it is verified that between 91 % and 93 % of the product runs through a 100 - μm sieve . therefore , it may be asserted that at least 91 % of the granulate is dispersed in particles that are approximately equal to the starting ones . the ibuprofen - disaggregating agent mixture ( 97 : 3 or 96 : 4 ) is compacted with a refrigerated flat roller compactor , working with the following operating constants : the selected machine operates at constant pressure regardless of the feed rate . under these operating conditions , the following granulometries were obtained ( 2 batches ): it must be noted that the granulate barely has any fines . if the granulate obtained had a number of fines ( for 125 μm ) greater than 5 %, it would be necessary to separate the fines by means of compaction recirculation thereof in order to obtain the desired granulates . since ibuprofen is greasy and fatty , it does not require lubrication in order to be compressed . since the granulate is dispersed in approximately the same particle sizes as the original , it does not require an external disaggregating agent . therefore , the granulate obtained in the preceding operation may be compressed without adding any other component . however , if the rate of production is very high and the granulate is heated during the compression action , it tends to melt and stick to the punches . 4 different forms or ways to handle the compression of the granulate have been tested : the granulate obtained is compressed in a machine at a low speed of rotation ( 16 - 20 rpm ) at a hardness of & gt ; 6 kp ( normally at a hardness of 8 to 10 kp ) and a disaggregation time of 2 - 4 minutes . the granulate obtained is compressed in said machine at a rate that is 70 % of the nominal rate . when the machine had been operating for approximately ½ hour , the tablets began to stick due to the heat produced in the machine during the compression action . 3rd form — equal to the 2nd form , but the granulate was at 10 ° c . : when the granulate was at 10 ° c ., the adhesion effect of the powder to the punches disappears and it is not observed during 1 hour of operation . equal to the 2nd form , but 1 % of adsorbent is added to the granulate . a quantity of 1 % of aerosil 200 ( 6 mg / tablet ) was added to the granulate . adhesion of the powder to the punch disappears and it is not observed during 2 hours of operation . the tablets obtained have the same characteristics as the previous ones and the operating conditions are identical to those of the 2nd form described . the disaggregation time of the tablet is approximately 2 minutes and the hardness is 8 kp . since it is expected that the activity of an anti - inflammatory and analgesic agent of the ibuprofen type be as quick as possible , the operating conditions that produce tablets with a disaggregation time & gt ; 3 minutes have been discarded . the hardness of the tablet does not vary when the operating conditions are 9 kn in a fast machine , or 15 kn , and tablet hardnesses ranging between 8 and 11 kp are obtained . however , the disaggregation times of the tablets are very different . in the 1st case ( 9 kn ), the disaggregation times are always less than 3 minutes , whereas in the 2nd case the disaggregation time is & gt ; 6 minutes . this specification makes it possible to quickly adjust the compression machine without having to wait for the dissolution rate assay , which would make the industrialisation thereof practically impossible . a study of the non - standard behaviour of ibuprofen tablets with granulates containing 96 % of active principle was also performed , and the following conclusions were reached : such different behaviours with relatively small changes in pressure are due to the fatty character of ibuprofen . in order for the tablet to disaggregate , it must have micropores on the surface , such that the water may penetrate at a high speed and the disaggregating agent may break the tablet by swelling , soaked in water . these micropores are easy to observe on the lower side of the tablet with a magnifying glass . when the micropores are reduced or cancelled due to the effect of the compression pressure , the disaggregation and subsequent release takes place by erosion , delaying and releasing the active principle according to a “ controlled - release ” behaviour of a lipid matrix . said lipid matrix is the active principle itself . an increase in the machine pressure does not lead to a greater hardness of the tablet , for which reason there is no direct relation greater hardness - greater disaggregation time . the formulations described above entail a number of advantages , which primarily revolve around the following aspects : minimal primary cost , i . e . formulation cost . very fast process , which may be adapted to continuous processes . low cost of the process . low energy consumption . easy industrial implementation , with closed designs and very few space needs . short “ cycle times ”, with a response of less than 24 hours . for the manufacturing of tablets composed of 600 mg / tablet , the steps are the following : sieve the ibuprofen and the sodium croscarmellose through a 1 - mm sieve and lift them to the 500 - litre “ biconical ” mixer . compact the mixture in a refrigerated roller compactor operating with the following constants : in the event that they are more than 5 %, run the granulate through a continuous rotary sieve with a 200 - 250 - μm mesh size . compress at a speed of rotation of 14 - 18 rpm with the following constants : weight : 600 mg hardness & gt ; 6 kp disaggregation time & lt ; 3 min . 3 . b . high - speed machine . compress at a speed of rotation greater than 60 rpm and with a pre - compression station . 3 . b . 1 — mix the granulate with 1 % of aerosil 200 for 5 min . the final machine pressure is 9 kn and the pre - compression pressure is 4 kn . 4 . 1 . 1 .— place approximately 6 litres of water in a tank under stirring ( turbomixer ) and , under constant stirring , add the 6 - cps hpmc , stirring until the dissolution thereof . 4 . 2 . 1 .— place the 625 - mg tablets weight / tablet ( 100 , 000 ) in a perforated drum ( accela - cotta ). 4 . 2 . 2 .— put the inlet air at 55 ° c .- 60 ° c ., keeping the drum in circulation at 1 - 2 rpm . 4 . 2 . 3 .— when the tablets have a temperature of 38 ° c .- 40 ° c ., place the drum at 6 rpm and begin atomisation with the following operating constants : atomisation rate : 110 - 120 ml / minute inlet air temperature : 55 ° c .- 60 ° c . outlet air temperature : 42 ° c .- 46 ° c . atomisation pressure : 3 - 4 bar once the atomisation is complete , discharge the drum and collect the tablets in sachets , keeping them in trays . the approximate atomisation time is between 1 hour and 1 h and 15 min per 63 - 63 - kg load . the increase in weight due to the coating must be between 5 and 6 mg / tablet .
by mixing ibuprofen and a disaggregating agent , the invention involves using these components in a proportion ranging between 96 % and 97 % by weight for ibuprofen , and between 3 % and 4 % for the disaggregating agent , which may be sodium croscarmellose , crospovidone or sodium carboxymethyl starch , as well as a mixture thereof . following the mixing of the raw materials , the mixture is subjected to compaction , granulation and subsequent compression , in order to finally give the tablet a coating ; this leads to a significant cost reduction and a significant reduction in the active principle release time , such that the pharmacological action is very fast in time .